Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 9/20 | 1.00 |
| ▸ | CYP19A1 | P11511 | 7/20 | 1.00 |
| ▸ | MAOA | P21397 | 1/20 | 1.00 |
| ▸ | PSMB5 | P28074 | 1/20 | 1.00 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.86 |
| ▸ | TUBB | P07437 | 1/20 | 0.86 |
| ▸ | YES1 | P07947 | 1/20 | 0.86 |
| ▸ | TUBA3C | P0DPH7 | 1/20 | 0.86 |
| ▸ | TUBA1B | P68363 | 1/20 | 0.86 |
| ▸ | TUBA4A | P68366 | 1/20 | 0.86 |
| ▸ | TUBB4B | P68371 | 1/20 | 0.86 |
| ▸ | TUBB3 | Q13509 | 1/20 | 0.86 |
| ▸ | TUBB2A | Q13885 | 1/20 | 0.86 |
| ▸ | TUBB8 | Q3ZCM7 | 1/20 | 0.86 |
| ▸ | TUBA3E | Q6PEY2 | 1/20 | 0.86 |
| ▸ | TUBA1A | Q71U36 | 1/20 | 0.86 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.86 |
| ▸ | TUBA1C | Q9BQE3 | 1/20 | 0.86 |
| ▸ | TUBB6 | Q9BUF5 | 1/20 | 0.86 |
| ▸ | TUBB2B | Q9BVA1 | 1/20 | 0.86 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| 7-Hydroxyflavanone SCHEMBL29843931 | 1.00 | MAOB (1.00) | MAOBCYP19A1MAOAPSMB5TUBB4A | |
| 7-Hydroxyflavanone SCHEMBL126599 | 1.00 | MAOB (1.00) | MAOBCYP19A1MAOAPSMB5TUBB4A | |
| 7-Hydroxyflavanone SCHEMBL1072683 | 1.00 | MAOB (1.00) | MAOBCYP19A1MAOAPSMB5TUBB4A | |
| Liquirtigenin SCHEMBL3120177 | 0.93 | MAOB (0.87) | MAOBCYP19A1MAOAPSMB5TUBB4A | |
| Liquirtigenin SCHEMBL1071066 | 0.92 | CYP19A1 (1.00) | MAOBCYP19A1MAOAPSMB5TUBB4A | |
| Liquirtigenin SCHEMBL26970367 | 0.92 | CYP19A1 (1.00) | MAOBCYP19A1MAOAPSMB5TUBB4A | |
| Liquirtigenin SCHEMBL74552 | 0.92 | CYP19A1 (1.00) | MAOBCYP19A1MAOAPSMB5TUBB4A | |
| Liquirtigenin SCHEMBL29552383 | 0.92 | CYP19A1 (1.00) | MAOBCYP19A1MAOAPSMB5TUBB4A | |
| Liquirtigenin SCHEMBL30352791 | 0.92 | CYP19A1 (1.00) | MAOBCYP19A1MAOAPSMB5TUBB4A | |
| Liquirtigenin SCHEMBL4649862 | 0.91 | CYP19A1 (0.97) | MAOBCYP19A1MAOAPSMB5TUBB4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 556 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025091065-A1 | FLAVONOID COMPOSITION | GRETALS AUSTRALIA PTY LTD (AU) | 2025-05-08 | — | — | WO | claimed |
| US-20240373850-A1 | Compositions comprising resinous exudate metabolites from plants of the genus Adesmia, used to control and treat infections in plant crops; and methods for controlling infections in plant crops. | PONTIFICIA UNIV CATOLICA DE VALPARAISO (CL) | 2024-11-14 | — | — | US | claimed |
| US-20240150797-A1 | BIOCATALYTICAL PRODUCTION OF DIHYDROCHALCONES | SYMRISE AG (DE) | 2024-05-09 | — | — | US | claimed |
| EP-4301865-A1 | BIOCATALYTICAL PRODUCTION OF DIHYDROCHALCONES | Symrise AG (DE) | 2024-01-10 | — | — | EP | claimed |
| CN-117242185-A | Biocatalytic preparation of dihydrochalcone | 西姆莱斯有限公司 | 2023-12-15 | — | — | CN | claimed |
| CN-116660543-A | Diagnostic and prognostic markers for nonalcoholic fatty liver disease and uses thereof | 中国人民解放军陆军军医大学第一附属医院 | 2023-08-29 | — | — | CN | claimed |
| US-20230172901-A1 | COMPOSITIONS AND METHODS FOR THE PROPHYLAXIS AND TREATMENT OF FIBROTIC AND INFLAMMATORY CONDITIONS | GRETALS AUSTRALIA PTY LTD (AU) | 2023-06-08 | — | — | US | claimed |
| EP-4146194-A1 | COMPOSITIONS AND METHODS FOR THE PROPHYLAXIS AND TREATMENT OF FIBROTIC AND INFLAMMATORY CONDITIONS | Gretals Australia Pty Ltd (AU) | 2023-03-15 | — | — | EP | claimed |
| WO-2022221968-A1 | COMPOSITIONS COMPRISING RESINOUS EXUDATE METABOLITES FROM PLANTS OF THE GENUS ADESMIA, USED TO CONTROL AND TREAT INFECTIONS IN PLANT CROPS; AND METHODS FOR CONTROLLING INFECTIONS IN PLANT CROPS | PONTIFICIA UNIVERSIDAD CATÓLICA DE VALPARAÍSO (CL) | 2022-10-27 | — | — | WO | claimed |
| WO-2022184248-A1 | BIOCATALYTICAL PRODUCTION OF DIHYDROCHALCONES | SYMRISE AG (DE) | 2022-09-09 | — | — | WO | claimed |
| WO-2021222987-A1 | COMPOSITIONS AND METHODS FOR THE PROPHYLAXIS AND TREATMENT OF FIBROTIC AND INFLAMMATORY CONDITIONS | GRETALS AUSTRALIA PTY LTD (AU) | 2021-11-11 | — | — | WO | claimed |
| US-11040079-B2 | Compositions derived from Galenia Africana and methods of use for cancer treatment | BIOPHARM NZ LIMITED (NZ) | 2021-06-22 | — | — | US | claimed |
| CN-112716933-A | Application of 7-hydroxyflavanone in preparation of medicine for promoting juvenile bone growth | 河南省洛阳正骨医院（河南省骨科医院） | 2021-04-30 | — | — | CN | claimed |
| EP-3558333-A1 | COMPOSITIONS DERIVED FROMGALENIA AFRICANA | Biopharm NZ Limited (NZ) | 2019-10-30 | — | — | EP | claimed |
| WO-2018116146-A1 | COMPOSITIONS DERIVED FROM GALENIA AFRICANA AND METHODS OF USE FOR CANCER TREATMENT | BIOPHARM NZ LIMITED (NZ) | 2018-06-28 | — | — | WO | claimed |
| US-20110020895-A1 | METHODS AND COMPOSITIONS FOR DETERMINING ISOMERASE ENZYMATIC ACTIVITY | SALK INSTITUTE FOR BIOLOGICAL STUDIES | 2011-01-27 | — | — | US | claimed |
| US-20080254519-A1 | Process for Producing Picolinic Acid Compounds | SHINDO KAZUTOSHI | 2008-10-16 | — | — | US | claimed |
| EP-1726645-A1 | PROCESS FOR PRODUCING PICOLINIC ACID COMPOUNDS | MARINE BIOTECHNOLOGY INSTITUTE CO., LTD. (JP) | 2006-11-29 | — | — | EP | claimed |
| US-20040096955-A1 | Methods and compositions for determining isomerase enzymatic activity | NATIONAL SCIENCE FOUNDATION | 2004-05-20 | — | — | US | claimed |
| WO-2002018604-A2 | METHODS AND COMPOSITIONS FOR DETERMINING ISOMERASE ENZYMATIC ACTIVITY | THE SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 2002-03-07 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240373850-A1 | Compositions comprising resinous exudate metabolites from plants of the genus Adesmia, used to control and treat infections in plant crops; and methods for controlling infections in plant crops. | ERG28, RXFP4, CROCC | MAOB 2261/4885CYP19A1 2372/4885MAOA 2174/4885 |
| US-20080254519-A1 | Process for Producing Picolinic Acid Compounds | HPD, PAH, DHPS | MAOB 294/4885CYP19A1 126/4885MAOA 187/4885 |
| US-20230172901-A1 | COMPOSITIONS AND METHODS FOR THE PROPHYLAXIS AND TREATMENT OF FIBROTIC AND INFLAMMATORY CONDITIONS | MMP1, COL1A1, SERPINB1 | MAOB 2184/4885CYP19A1 3035/4885MAOA 2155/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.